Linda Watkins
Concepts (966)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuralgia | 41 | 2026 | 140 | 11.430 |
Why?
| | Hyperalgesia | 71 | 2026 | 127 | 11.320 |
Why?
| | Toll-Like Receptor 4 | 46 | 2023 | 276 | 7.980 |
Why?
| | Pain | 62 | 2026 | 789 | 7.420 |
Why?
| | Microglia | 55 | 2024 | 270 | 6.870 |
Why?
| | Rats, Sprague-Dawley | 241 | 2026 | 2524 | 6.670 |
Why?
| | Spinal Cord | 50 | 2023 | 382 | 5.780 |
Why?
| | Rats | 283 | 2026 | 5584 | 5.670 |
Why?
| | Morphine | 41 | 2020 | 168 | 5.430 |
Why?
| | Neuroglia | 39 | 2015 | 173 | 4.600 |
Why?
| | Neuroimmunomodulation | 35 | 2025 | 67 | 4.400 |
Why?
| | Interleukin-10 | 23 | 2024 | 309 | 3.820 |
Why?
| | Analgesics, Opioid | 38 | 2019 | 1149 | 3.730 |
Why?
| | Animals | 365 | 2026 | 38030 | 3.190 |
Why?
| | Chronic Pain | 10 | 2026 | 291 | 3.110 |
Why?
| | Cytokines | 53 | 2024 | 2067 | 3.090 |
Why?
| | Interleukin-1beta | 33 | 2023 | 389 | 2.870 |
Why?
| | Interleukin-1 | 51 | 2011 | 961 | 2.800 |
Why?
| | Spinal Cord Injuries | 9 | 2021 | 234 | 2.720 |
Why?
| | Stress, Psychological | 60 | 2020 | 1146 | 2.700 |
Why?
| | Inflammation | 51 | 2024 | 2878 | 2.480 |
Why?
| | Sciatic Neuropathy | 13 | 2023 | 30 | 2.440 |
Why?
| | Behavior, Animal | 55 | 2020 | 519 | 2.430 |
Why?
| | Lymphocyte Antigen 96 | 12 | 2019 | 23 | 2.380 |
Why?
| | Lipopolysaccharides | 52 | 2023 | 858 | 2.370 |
Why?
| | Signal Transduction | 42 | 2025 | 5216 | 2.300 |
Why?
| | Genetic Therapy | 16 | 2024 | 316 | 2.230 |
Why?
| | Injections, Spinal | 39 | 2018 | 119 | 2.210 |
Why?
| | Pain Threshold | 23 | 2019 | 72 | 2.200 |
Why?
| | Central Nervous System | 13 | 2018 | 282 | 2.130 |
Why?
| | Hippocampus | 51 | 2020 | 971 | 2.120 |
Why?
| | Stress, Physiological | 45 | 2017 | 443 | 2.010 |
Why?
| | Pain Measurement | 37 | 2024 | 561 | 1.970 |
Why?
| | Narcotic Antagonists | 20 | 2020 | 203 | 1.920 |
Why?
| | Corticosterone | 33 | 2019 | 241 | 1.920 |
Why?
| | Inflammasomes | 9 | 2023 | 144 | 1.920 |
Why?
| | Inflammation Mediators | 16 | 2020 | 506 | 1.770 |
Why?
| | Analgesia | 13 | 2015 | 106 | 1.750 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 69 | 1.740 |
Why?
| | Naltrexone | 19 | 2023 | 115 | 1.710 |
Why?
| | Raphe Nuclei | 30 | 2014 | 111 | 1.690 |
Why?
| | Adenosine A2 Receptor Agonists | 4 | 2018 | 23 | 1.670 |
Why?
| | Male | 286 | 2026 | 72842 | 1.660 |
Why?
| | Disease Models, Animal | 46 | 2024 | 4560 | 1.590 |
Why?
| | HIV Envelope Protein gp120 | 12 | 2010 | 55 | 1.580 |
Why?
| | Vagus Nerve | 16 | 2001 | 92 | 1.500 |
Why?
| | Plasmids | 9 | 2024 | 373 | 1.460 |
Why?
| | Sciatic Nerve | 11 | 2024 | 62 | 1.440 |
Why?
| | Fear | 34 | 2020 | 368 | 1.440 |
Why?
| | Peripheral Nervous System Diseases | 10 | 2012 | 134 | 1.420 |
Why?
| | Naloxone | 16 | 2019 | 131 | 1.370 |
Why?
| | Prefrontal Cortex | 20 | 2018 | 334 | 1.340 |
Why?
| | HMGB1 Protein | 12 | 2019 | 51 | 1.340 |
Why?
| | Helplessness, Learned | 21 | 2012 | 67 | 1.300 |
Why?
| | Brain | 34 | 2024 | 2947 | 1.260 |
Why?
| | Immune System | 9 | 2026 | 180 | 1.240 |
Why?
| | Minocycline | 8 | 2017 | 23 | 1.220 |
Why?
| | Encephalitis | 10 | 2018 | 142 | 1.210 |
Why?
| | Receptors, Interleukin-1 | 17 | 2016 | 211 | 1.150 |
Why?
| | Neurons | 26 | 2022 | 1649 | 1.150 |
Why?
| | Electroshock | 61 | 2018 | 145 | 1.120 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 11 | 2023 | 166 | 1.120 |
Why?
| | Astrocytes | 10 | 2019 | 228 | 1.120 |
Why?
| | Glucocorticoids | 17 | 2019 | 531 | 1.100 |
Why?
| | Tumor Necrosis Factor-alpha | 27 | 2019 | 1217 | 1.090 |
Why?
| | Serotonin | 32 | 2020 | 297 | 1.070 |
Why?
| | Peripheral Nerve Injuries | 5 | 2023 | 38 | 1.070 |
Why?
| | Piperidines | 5 | 2018 | 222 | 1.060 |
Why?
| | Escape Reaction | 25 | 2014 | 55 | 1.060 |
Why?
| | Conditioning, Classical | 11 | 2020 | 119 | 1.050 |
Why?
| | Somatosensory Cortex | 3 | 2026 | 42 | 1.050 |
Why?
| | Toll-Like Receptor 2 | 7 | 2021 | 125 | 1.020 |
Why?
| | Pain Management | 8 | 2021 | 410 | 1.020 |
Why?
| | Nucleus Accumbens | 9 | 2019 | 134 | 1.020 |
Why?
| | Dependovirus | 2 | 2024 | 78 | 0.990 |
Why?
| | Central Nervous System Stimulants | 6 | 2019 | 185 | 0.970 |
Why?
| | Memory Disorders | 15 | 2020 | 197 | 0.950 |
Why?
| | Dose-Response Relationship, Drug | 41 | 2023 | 2028 | 0.890 |
Why?
| | Osteoarthritis | 2 | 2020 | 200 | 0.890 |
Why?
| | Conditioning, Operant | 13 | 2017 | 94 | 0.880 |
Why?
| | Escherichia coli Infections | 15 | 2014 | 125 | 0.870 |
Why?
| | MicroRNAs | 3 | 2021 | 686 | 0.860 |
Why?
| | Acute Pain | 1 | 2026 | 58 | 0.860 |
Why?
| | Low-Level Light Therapy | 1 | 2024 | 7 | 0.850 |
Why?
| | Dopamine | 8 | 2019 | 295 | 0.840 |
Why?
| | RNA, Messenger | 26 | 2017 | 2803 | 0.820 |
Why?
| | Circadian Rhythm | 8 | 2019 | 512 | 0.820 |
Why?
| | Ventral Tegmental Area | 4 | 2019 | 62 | 0.810 |
Why?
| | Glucuronides | 2 | 2014 | 18 | 0.810 |
Why?
| | Vagotomy | 15 | 2001 | 33 | 0.810 |
Why?
| | Alarmins | 5 | 2018 | 27 | 0.800 |
Why?
| | Fever | 11 | 2011 | 319 | 0.800 |
Why?
| | Posterior Horn Cells | 2 | 2019 | 10 | 0.790 |
Why?
| | Ganglia, Spinal | 6 | 2016 | 88 | 0.790 |
Why?
| | Psoriasis | 1 | 2024 | 115 | 0.780 |
Why?
| | Cocaine | 5 | 2023 | 161 | 0.770 |
Why?
| | Narcotics | 8 | 2014 | 58 | 0.770 |
Why?
| | Motor Activity | 21 | 2023 | 718 | 0.760 |
Why?
| | Physical Stimulation | 13 | 2014 | 68 | 0.760 |
Why?
| | Aging | 16 | 2021 | 1969 | 0.740 |
Why?
| | Morphine Derivatives | 2 | 2014 | 19 | 0.740 |
Why?
| | Analysis of Variance | 27 | 2018 | 1300 | 0.730 |
Why?
| | Pyridines | 7 | 2017 | 609 | 0.720 |
Why?
| | Chemokines, CX3C | 4 | 2005 | 10 | 0.720 |
Why?
| | Toll-Like Receptors | 6 | 2017 | 193 | 0.720 |
Why?
| | Drug Delivery Systems | 5 | 2024 | 381 | 0.690 |
Why?
| | Rats, Inbred F344 | 19 | 2018 | 268 | 0.690 |
Why?
| | Drug Tolerance | 6 | 2017 | 99 | 0.690 |
Why?
| | Methamphetamine | 3 | 2019 | 74 | 0.680 |
Why?
| | Time Factors | 42 | 2019 | 7123 | 0.680 |
Why?
| | Sciatica | 6 | 2012 | 8 | 0.670 |
Why?
| | Phenethylamines | 2 | 2018 | 16 | 0.650 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 477 | 0.650 |
Why?
| | Amygdala | 10 | 2017 | 199 | 0.630 |
Why?
| | Migraine Disorders | 3 | 2017 | 114 | 0.630 |
Why?
| | Interleukin-6 | 15 | 2014 | 776 | 0.630 |
Why?
| | Nociceptors | 8 | 2006 | 40 | 0.620 |
Why?
| | Nicotinic Agonists | 2 | 2012 | 135 | 0.620 |
Why?
| | Anxiety | 15 | 2020 | 1118 | 0.610 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 14 | 2012 | 253 | 0.610 |
Why?
| | Arthralgia | 1 | 2020 | 61 | 0.610 |
Why?
| | Laparotomy | 5 | 2020 | 113 | 0.590 |
Why?
| | Gene Expression Regulation | 19 | 2019 | 2597 | 0.590 |
Why?
| | Defecation | 1 | 2019 | 18 | 0.580 |
Why?
| | Receptors, Nicotinic | 2 | 2012 | 327 | 0.570 |
Why?
| | Chronobiology Disorders | 1 | 2018 | 16 | 0.570 |
Why?
| | Substance-Related Disorders | 4 | 2024 | 1102 | 0.570 |
Why?
| | Adenosine | 2 | 2018 | 255 | 0.570 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 611 | 0.570 |
Why?
| | Synapses | 1 | 2022 | 439 | 0.550 |
Why?
| | Neural Pathways | 13 | 2026 | 313 | 0.550 |
Why?
| | Spinal Cord Dorsal Horn | 3 | 2019 | 5 | 0.550 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 489 | 0.550 |
Why?
| | Sex Characteristics | 5 | 2018 | 782 | 0.530 |
Why?
| | Immunity, Innate | 14 | 2019 | 835 | 0.520 |
Why?
| | Neurons, Afferent | 4 | 2007 | 102 | 0.520 |
Why?
| | Humans | 95 | 2026 | 145474 | 0.520 |
Why?
| | Neuroprotective Agents | 3 | 2015 | 147 | 0.520 |
Why?
| | Trigeminal Caudal Nucleus | 1 | 2017 | 1 | 0.510 |
Why?
| | Contusions | 1 | 2017 | 25 | 0.510 |
Why?
| | Ethanol | 5 | 2014 | 631 | 0.510 |
Why?
| | Proto-Oncogene Proteins c-fos | 14 | 2018 | 196 | 0.500 |
Why?
| | Facial Nerve Injuries | 1 | 2016 | 3 | 0.500 |
Why?
| | Macrophages | 11 | 2017 | 1507 | 0.500 |
Why?
| | Reactive Nitrogen Species | 1 | 2016 | 16 | 0.500 |
Why?
| | Spinal Injuries | 1 | 2017 | 60 | 0.500 |
Why?
| | Membrane Proteins | 5 | 2010 | 1164 | 0.500 |
Why?
| | Facial Nerve | 1 | 2016 | 39 | 0.490 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 6 | 0.490 |
Why?
| | Cells, Cultured | 17 | 2020 | 4148 | 0.480 |
Why?
| | Reward | 8 | 2015 | 248 | 0.480 |
Why?
| | DNA | 6 | 2024 | 1435 | 0.480 |
Why?
| | Catheters, Indwelling | 3 | 2012 | 96 | 0.480 |
Why?
| | NADPH Oxidases | 1 | 2016 | 122 | 0.470 |
Why?
| | Reaction Time | 17 | 2012 | 433 | 0.470 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2014 | 125 | 0.470 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 231 | 0.460 |
Why?
| | Catheterization | 6 | 2007 | 183 | 0.460 |
Why?
| | Xanthines | 2 | 2014 | 23 | 0.460 |
Why?
| | Memory | 10 | 2018 | 295 | 0.460 |
Why?
| | Hindlimb | 3 | 2013 | 132 | 0.450 |
Why?
| | Excitatory Amino Acid Transporter 2 | 2 | 2016 | 14 | 0.440 |
Why?
| | Dorsal Raphe Nucleus | 4 | 2020 | 31 | 0.440 |
Why?
| | Microinjections | 19 | 2018 | 92 | 0.440 |
Why?
| | Paralysis | 2 | 2015 | 69 | 0.430 |
Why?
| | Liver | 6 | 2019 | 1896 | 0.430 |
Why?
| | Endotoxins | 5 | 2012 | 217 | 0.430 |
Why?
| | Xenobiotics | 1 | 2015 | 30 | 0.430 |
Why?
| | Resilience, Psychological | 3 | 2018 | 149 | 0.420 |
Why?
| | Gliosis | 4 | 2013 | 30 | 0.410 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1996 | 0.400 |
Why?
| | Chronic Disease | 11 | 2017 | 1808 | 0.400 |
Why?
| | Fatigue | 1 | 2016 | 364 | 0.400 |
Why?
| | Neuropharmacology | 1 | 2013 | 4 | 0.400 |
Why?
| | Disease | 4 | 1999 | 96 | 0.390 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 143 | 0.390 |
Why?
| | Corticotropin-Releasing Hormone | 7 | 2005 | 72 | 0.380 |
Why?
| | Hot Temperature | 10 | 2009 | 396 | 0.380 |
Why?
| | Glucuronic Acid | 1 | 2013 | 30 | 0.380 |
Why?
| | Quinuclidines | 1 | 2012 | 11 | 0.380 |
Why?
| | Allergy and Immunology | 1 | 2013 | 43 | 0.380 |
Why?
| | HSP90 Heat-Shock Proteins | 2 | 2010 | 46 | 0.370 |
Why?
| | Injections, Intraperitoneal | 16 | 2009 | 116 | 0.360 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2014 | 119 | 0.360 |
Why?
| | Models, Animal | 1 | 2014 | 393 | 0.360 |
Why?
| | Estradiol | 2 | 2014 | 515 | 0.360 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1180 | 0.360 |
Why?
| | Facial Pain | 1 | 2012 | 12 | 0.360 |
Why?
| | Exploratory Behavior | 7 | 2018 | 85 | 0.360 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.360 |
Why?
| | Protein Kinase C | 1 | 2013 | 251 | 0.350 |
Why?
| | Hyperesthesia | 3 | 2007 | 6 | 0.350 |
Why?
| | Mice | 24 | 2024 | 18329 | 0.350 |
Why?
| | Neuralgia, Postherpetic | 1 | 2012 | 40 | 0.350 |
Why?
| | NF-kappa B | 8 | 2019 | 666 | 0.350 |
Why?
| | Complement System Proteins | 2 | 2005 | 314 | 0.340 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 49 | 0.340 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2009 | 154 | 0.330 |
Why?
| | CD11b Antigen | 6 | 2010 | 60 | 0.330 |
Why?
| | Animals, Newborn | 14 | 2019 | 891 | 0.330 |
Why?
| | Female | 36 | 2026 | 78844 | 0.320 |
Why?
| | Avoidance Learning | 5 | 2018 | 63 | 0.320 |
Why?
| | Drug-Seeking Behavior | 2 | 2023 | 22 | 0.320 |
Why?
| | Ceftriaxone | 1 | 2010 | 21 | 0.320 |
Why?
| | Diet, High-Fat | 3 | 2017 | 266 | 0.320 |
Why?
| | Pyrazoles | 7 | 2017 | 517 | 0.310 |
Why?
| | Chemokines | 3 | 2021 | 217 | 0.310 |
Why?
| | Indolizines | 6 | 2017 | 13 | 0.310 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2010 | 44 | 0.310 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 11 | 2012 | 977 | 0.310 |
Why?
| | Receptor, Adenosine A2A | 1 | 2009 | 23 | 0.300 |
Why?
| | Genetic Vectors | 4 | 2024 | 335 | 0.300 |
Why?
| | Up-Regulation | 4 | 2013 | 847 | 0.300 |
Why?
| | Morphinans | 3 | 2015 | 8 | 0.300 |
Why?
| | Self Administration | 5 | 2023 | 122 | 0.300 |
Why?
| | Receptors, Opioid, mu | 6 | 2020 | 66 | 0.300 |
Why?
| | Constriction, Pathologic | 4 | 2016 | 249 | 0.300 |
Why?
| | Respiratory Insufficiency | 2 | 2014 | 326 | 0.290 |
Why?
| | Formaldehyde | 6 | 2013 | 65 | 0.290 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2012 | 848 | 0.290 |
Why?
| | Meninges | 2 | 2006 | 49 | 0.290 |
Why?
| | Sialoglycoproteins | 8 | 2004 | 157 | 0.290 |
Why?
| | Cell Line | 13 | 2019 | 2823 | 0.290 |
Why?
| | Neurotransmitter Agents | 2 | 2006 | 84 | 0.280 |
Why?
| | Behavior | 3 | 2006 | 89 | 0.280 |
Why?
| | Mice, Inbred BALB C | 7 | 2014 | 1261 | 0.280 |
Why?
| | Functional Laterality | 7 | 2016 | 240 | 0.280 |
Why?
| | HEK293 Cells | 6 | 2024 | 741 | 0.270 |
Why?
| | Endothelial Cells | 1 | 2014 | 874 | 0.270 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2004 | 162 | 0.270 |
Why?
| | Injections, Subcutaneous | 9 | 2012 | 170 | 0.270 |
Why?
| | Wakefulness | 1 | 2009 | 170 | 0.270 |
Why?
| | Glutamic Acid | 1 | 2010 | 255 | 0.270 |
Why?
| | Face | 1 | 2009 | 174 | 0.270 |
Why?
| | Parkinson Disease | 1 | 2014 | 599 | 0.270 |
Why?
| | Cerebral Cortex | 4 | 2018 | 473 | 0.270 |
Why?
| | Receptors, Opioid | 3 | 2011 | 21 | 0.270 |
Why?
| | Receptors, Immunologic | 3 | 2019 | 208 | 0.270 |
Why?
| | Microdialysis | 13 | 2012 | 56 | 0.270 |
Why?
| | Transgenes | 2 | 2024 | 190 | 0.260 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2011 | 185 | 0.260 |
Why?
| | Molecular Dynamics Simulation | 3 | 2019 | 265 | 0.260 |
Why?
| | Drug Design | 2 | 2010 | 175 | 0.260 |
Why?
| | Receptors, Complement | 2 | 2005 | 123 | 0.260 |
Why?
| | Cues | 8 | 2013 | 327 | 0.260 |
Why?
| | Clozapine | 2 | 2018 | 20 | 0.260 |
Why?
| | Constriction | 3 | 2023 | 45 | 0.260 |
Why?
| | Biomedical Research | 2 | 2013 | 717 | 0.260 |
Why?
| | Alkaline Phosphatase | 3 | 2014 | 144 | 0.250 |
Why?
| | Mycobacterium | 2 | 2018 | 101 | 0.250 |
Why?
| | Locomotion | 2 | 2018 | 101 | 0.250 |
Why?
| | Crotalid Venoms | 2 | 2004 | 30 | 0.250 |
Why?
| | Drug Administration Schedule | 7 | 2019 | 782 | 0.250 |
Why?
| | Nitric Oxide | 7 | 2019 | 892 | 0.250 |
Why?
| | Phospholipases A | 2 | 2004 | 97 | 0.250 |
Why?
| | Hypothalamus | 5 | 2008 | 163 | 0.250 |
Why?
| | Chemokine CX3CL1 | 5 | 2008 | 25 | 0.250 |
Why?
| | Immunocompetence | 1 | 2006 | 46 | 0.240 |
Why?
| | Nerve Tissue Proteins | 5 | 2011 | 591 | 0.240 |
Why?
| | Immunohistochemistry | 17 | 2010 | 1716 | 0.240 |
Why?
| | Transfection | 3 | 2018 | 926 | 0.240 |
Why?
| | Dinoprostone | 4 | 2014 | 180 | 0.240 |
Why?
| | Cognition | 6 | 2018 | 1266 | 0.240 |
Why?
| | Limbic System | 3 | 2019 | 55 | 0.240 |
Why?
| | Citrates | 6 | 2006 | 41 | 0.240 |
Why?
| | Corpus Striatum | 3 | 2018 | 179 | 0.240 |
Why?
| | Cisterna Magna | 4 | 2013 | 8 | 0.230 |
Why?
| | Neuronal Plasticity | 3 | 2022 | 305 | 0.230 |
Why?
| | Ketamine | 3 | 2018 | 137 | 0.230 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2012 | 199 | 0.230 |
Why?
| | Freezing Reaction, Cataleptic | 4 | 2013 | 27 | 0.230 |
Why?
| | Extinction, Psychological | 5 | 2023 | 92 | 0.230 |
Why?
| | Adaptation, Psychological | 2 | 2010 | 716 | 0.230 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2006 | 178 | 0.230 |
Why?
| | Paclitaxel | 1 | 2006 | 257 | 0.230 |
Why?
| | Bacterial Infections | 4 | 2009 | 246 | 0.220 |
Why?
| | Oxycodone | 3 | 2019 | 52 | 0.220 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1480 | 0.220 |
Why?
| | Protein Binding | 9 | 2018 | 2238 | 0.220 |
Why?
| | Arousal | 6 | 2002 | 157 | 0.220 |
Why?
| | Aminoquinolines | 1 | 2024 | 18 | 0.220 |
Why?
| | Spinal Nerve Roots | 3 | 2012 | 29 | 0.210 |
Why?
| | Antibodies | 6 | 2018 | 397 | 0.210 |
Why?
| | Analgesics | 5 | 2020 | 231 | 0.210 |
Why?
| | Cyclooxygenase 2 | 4 | 2019 | 166 | 0.210 |
Why?
| | Models, Immunological | 1 | 2005 | 99 | 0.210 |
Why?
| | Infrared Rays | 1 | 2024 | 24 | 0.210 |
Why?
| | Nitric Oxide Synthase | 2 | 2004 | 234 | 0.210 |
Why?
| | Ligation | 3 | 2013 | 91 | 0.210 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 127 | 0.210 |
Why?
| | Brain Mapping | 8 | 2018 | 538 | 0.210 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2008 | 80 | 0.210 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 345 | 0.210 |
Why?
| | Vesiculovirus | 1 | 2024 | 17 | 0.210 |
Why?
| | Injections, Intraventricular | 13 | 2015 | 59 | 0.210 |
Why?
| | Models, Neurological | 2 | 2003 | 250 | 0.210 |
Why?
| | Central Nervous System Agents | 1 | 2003 | 7 | 0.200 |
Why?
| | Cholecystokinin | 4 | 2000 | 15 | 0.200 |
Why?
| | Body Fluids | 1 | 2004 | 71 | 0.200 |
Why?
| | Gap Junctions | 1 | 2004 | 67 | 0.200 |
Why?
| | Glial Fibrillary Acidic Protein | 8 | 2015 | 122 | 0.200 |
Why?
| | Transduction, Genetic | 1 | 2024 | 132 | 0.200 |
Why?
| | Carrier Proteins | 5 | 2015 | 728 | 0.200 |
Why?
| | Lumbosacral Region | 4 | 2013 | 59 | 0.200 |
Why?
| | Neural Inhibition | 2 | 2010 | 178 | 0.200 |
Why?
| | Norepinephrine | 5 | 2005 | 201 | 0.200 |
Why?
| | Central Nervous System Diseases | 2 | 2017 | 74 | 0.200 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 246 | 0.190 |
Why?
| | Antigens, CD | 4 | 2017 | 558 | 0.190 |
Why?
| | Mice, Knockout | 5 | 2021 | 3124 | 0.190 |
Why?
| | Mifepristone | 6 | 2019 | 53 | 0.190 |
Why?
| | Adrenalectomy | 10 | 2014 | 68 | 0.190 |
Why?
| | Enzyme Inhibitors | 6 | 2007 | 820 | 0.190 |
Why?
| | Freund's Adjuvant | 2 | 2013 | 18 | 0.190 |
Why?
| | Pituitary Gland | 6 | 2004 | 149 | 0.190 |
Why?
| | Receptors, Glucocorticoid | 5 | 2016 | 129 | 0.190 |
Why?
| | Learning | 7 | 2018 | 443 | 0.190 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 207 | 0.190 |
Why?
| | Gene Expression | 8 | 2020 | 1476 | 0.180 |
Why?
| | Illness Behavior | 2 | 2014 | 9 | 0.180 |
Why?
| | Brain Chemistry | 3 | 2004 | 119 | 0.180 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2021 | 55 | 0.180 |
Why?
| | Opioid-Related Disorders | 5 | 2017 | 602 | 0.180 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 2007 | 94 | 0.180 |
Why?
| | Random Allocation | 6 | 2016 | 365 | 0.180 |
Why?
| | Synaptic Transmission | 4 | 2010 | 292 | 0.180 |
Why?
| | Caspase 1 | 3 | 2020 | 145 | 0.180 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 264 | 0.180 |
Why?
| | Social Behavior | 8 | 2018 | 284 | 0.180 |
Why?
| | Spleen | 7 | 2014 | 508 | 0.170 |
Why?
| | Cocaine-Related Disorders | 1 | 2023 | 133 | 0.170 |
Why?
| | Psychoneuroimmunology | 3 | 2002 | 9 | 0.170 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 467 | 0.170 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 439 | 0.170 |
Why?
| | Immunity, Cellular | 2 | 2002 | 274 | 0.170 |
Why?
| | Affect | 3 | 2018 | 320 | 0.170 |
Why?
| | GABA Antagonists | 4 | 2010 | 34 | 0.170 |
Why?
| | Indoles | 4 | 2013 | 507 | 0.170 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2012 | 94 | 0.170 |
Why?
| | Tail | 11 | 2007 | 28 | 0.170 |
Why?
| | Central Nervous System Depressants | 2 | 2014 | 84 | 0.160 |
Why?
| | Zymosan | 4 | 2005 | 39 | 0.160 |
Why?
| | 8-Hydroxy-2-(di-n-propylamino)tetralin | 4 | 2009 | 9 | 0.160 |
Why?
| | Receptors, HIV | 3 | 2004 | 22 | 0.160 |
Why?
| | Touch | 3 | 2013 | 39 | 0.160 |
Why?
| | Cell Communication | 3 | 2009 | 328 | 0.160 |
Why?
| | Dexamethasone | 5 | 2012 | 365 | 0.160 |
Why?
| | Body Temperature | 5 | 2002 | 227 | 0.160 |
Why?
| | Neurogenesis | 1 | 2022 | 157 | 0.160 |
Why?
| | Fentanyl | 2 | 2019 | 128 | 0.160 |
Why?
| | Drug Interactions | 6 | 2008 | 405 | 0.160 |
Why?
| | Receptors, Cytokine | 3 | 2004 | 36 | 0.160 |
Why?
| | Models, Molecular | 5 | 2012 | 1598 | 0.160 |
Why?
| | Thoracic Vertebrae | 2 | 2019 | 82 | 0.160 |
Why?
| | Convulsants | 4 | 1998 | 8 | 0.160 |
Why?
| | Specific Pathogen-Free Organisms | 5 | 2004 | 58 | 0.160 |
Why?
| | AIDS Dementia Complex | 1 | 2000 | 52 | 0.160 |
Why?
| | Drug Synergism | 4 | 2015 | 354 | 0.160 |
Why?
| | Dogs | 2 | 2020 | 458 | 0.150 |
Why?
| | Carbolines | 4 | 1998 | 35 | 0.150 |
Why?
| | Lithium Chloride | 3 | 1994 | 14 | 0.150 |
Why?
| | Skin | 1 | 2024 | 753 | 0.150 |
Why?
| | Lovastatin | 1 | 2019 | 37 | 0.150 |
Why?
| | Antibody Formation | 6 | 2002 | 288 | 0.150 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 4 | 2004 | 30 | 0.150 |
Why?
| | Hemocyanins | 8 | 2003 | 61 | 0.150 |
Why?
| | Microfilament Proteins | 3 | 2016 | 135 | 0.150 |
Why?
| | Thalamus | 2 | 2018 | 129 | 0.150 |
Why?
| | Immunization | 4 | 2018 | 375 | 0.150 |
Why?
| | CLOCK Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Tumor Necrosis Factor Decoy Receptors | 3 | 2004 | 8 | 0.140 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2018 | 7 | 0.140 |
Why?
| | Diaphragm | 5 | 2001 | 48 | 0.140 |
Why?
| | Pituitary-Adrenal System | 5 | 2004 | 164 | 0.140 |
Why?
| | Receptors, Purinergic P1 | 1 | 2018 | 30 | 0.140 |
Why?
| | Motor Disorders | 1 | 2018 | 17 | 0.140 |
Why?
| | Calcium-Binding Proteins | 3 | 2016 | 221 | 0.140 |
Why?
| | Medulla Oblongata | 2 | 2014 | 37 | 0.140 |
Why?
| | Restraint, Physical | 11 | 2007 | 75 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT1A | 2 | 2011 | 36 | 0.140 |
Why?
| | Recombinant Proteins | 8 | 2005 | 1368 | 0.140 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5983 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 333 | 0.140 |
Why?
| | Designer Drugs | 1 | 2018 | 7 | 0.140 |
Why?
| | Molecular Docking Simulation | 2 | 2018 | 119 | 0.140 |
Why?
| | Septal Nuclei | 2 | 2011 | 24 | 0.140 |
Why?
| | Maze Learning | 2 | 2016 | 105 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2018 | 52 | 0.140 |
Why?
| | Abdomen | 1 | 1999 | 142 | 0.140 |
Why?
| | Body Weight | 4 | 2018 | 971 | 0.140 |
Why?
| | Bacterial Vaccines | 1 | 2018 | 63 | 0.140 |
Why?
| | Transcortin | 4 | 1999 | 14 | 0.130 |
Why?
| | Probiotics | 1 | 2018 | 61 | 0.130 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 27 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 428 | 0.130 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 108 | 0.130 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2017 | 12 | 0.130 |
Why?
| | Muscimol | 7 | 2011 | 23 | 0.130 |
Why?
| | Brain Injuries | 2 | 2013 | 507 | 0.130 |
Why?
| | Amphetamine | 3 | 2010 | 38 | 0.130 |
Why?
| | Methadone | 2 | 2010 | 122 | 0.130 |
Why?
| | Nitrites | 2 | 2016 | 87 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 456 | 0.130 |
Why?
| | Acoustic Stimulation | 5 | 2011 | 333 | 0.130 |
Why?
| | Biomarkers | 5 | 2012 | 4295 | 0.130 |
Why?
| | Taste | 3 | 2008 | 238 | 0.130 |
Why?
| | Facial Nucleus | 1 | 2016 | 1 | 0.130 |
Why?
| | Rats, Inbred Strains | 7 | 2017 | 321 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2018 | 181 | 0.130 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 3 | 0.120 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 4 | 0.120 |
Why?
| | Habenula | 1 | 2016 | 13 | 0.120 |
Why?
| | Dura Mater | 1 | 2017 | 40 | 0.120 |
Why?
| | Toll-Like Receptor 5 | 1 | 2016 | 18 | 0.120 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 13 | 0.120 |
Why?
| | Spatial Memory | 1 | 2016 | 27 | 0.120 |
Why?
| | Down-Regulation | 2 | 2017 | 618 | 0.120 |
Why?
| | Models, Biological | 3 | 2017 | 1764 | 0.120 |
Why?
| | CX3C Chemokine Receptor 1 | 3 | 2004 | 19 | 0.120 |
Why?
| | Guanidines | 3 | 2003 | 39 | 0.120 |
Why?
| | Radiculopathy | 2 | 2014 | 38 | 0.120 |
Why?
| | Brain Ischemia | 2 | 2018 | 359 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 2 | 2018 | 355 | 0.120 |
Why?
| | Neurogenic Inflammation | 1 | 2016 | 2 | 0.120 |
Why?
| | Hydrazones | 3 | 2003 | 26 | 0.120 |
Why?
| | Cell Count | 9 | 2009 | 319 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 1997 | 128 | 0.120 |
Why?
| | Flumazenil | 1 | 1995 | 8 | 0.120 |
Why?
| | Anilides | 3 | 2003 | 84 | 0.120 |
Why?
| | Nociception | 2 | 2015 | 17 | 0.110 |
Why?
| | Life Expectancy | 1 | 2016 | 73 | 0.110 |
Why?
| | Physical Conditioning, Animal | 3 | 2014 | 242 | 0.110 |
Why?
| | Isomerism | 2 | 2018 | 56 | 0.110 |
Why?
| | Reflex, Abnormal | 1 | 2014 | 8 | 0.110 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.110 |
Why?
| | Autoimmunity | 1 | 2021 | 933 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 340 | 0.110 |
Why?
| | NG-Nitroarginine Methyl Ester | 2 | 2005 | 49 | 0.110 |
Why?
| | Picrotoxin | 5 | 2018 | 12 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 649 | 0.110 |
Why?
| | Mice, Inbred C3H | 1 | 2015 | 254 | 0.110 |
Why?
| | Drug Administration Routes | 2 | 2012 | 42 | 0.110 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 59 | 0.110 |
Why?
| | Neuropeptides | 1 | 1994 | 75 | 0.110 |
Why?
| | Body Temperature Regulation | 2 | 2009 | 105 | 0.110 |
Why?
| | Memory, Long-Term | 3 | 2020 | 12 | 0.100 |
Why?
| | Morphine Dependence | 2 | 2011 | 5 | 0.100 |
Why?
| | Receptors, GABA-A | 1 | 1995 | 137 | 0.100 |
Why?
| | Circadian Clocks | 1 | 2014 | 59 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2015 | 139 | 0.100 |
Why?
| | Host-Pathogen Interactions | 3 | 2012 | 361 | 0.100 |
Why?
| | PPAR gamma | 1 | 2015 | 178 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 838 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 73 | 0.100 |
Why?
| | Nervous System | 1 | 1994 | 69 | 0.100 |
Why?
| | Brain Stem | 2 | 2010 | 98 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 574 | 0.100 |
Why?
| | Phosphorylation | 3 | 2012 | 1707 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1048 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 382 | 0.100 |
Why?
| | Escherichia coli | 5 | 2016 | 835 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2012 | 870 | 0.100 |
Why?
| | Pentamidine | 1 | 2012 | 3 | 0.090 |
Why?
| | Running | 2 | 2017 | 233 | 0.090 |
Why?
| | Interleukins | 2 | 2006 | 248 | 0.090 |
Why?
| | Swimming | 1 | 2013 | 54 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2016 | 397 | 0.090 |
Why?
| | Heroin | 1 | 2013 | 29 | 0.090 |
Why?
| | Viral Matrix Proteins | 1 | 2012 | 28 | 0.090 |
Why?
| | Recovery of Function | 1 | 2017 | 716 | 0.090 |
Why?
| | Rats, Wistar | 4 | 2016 | 450 | 0.090 |
Why?
| | Rifampin | 1 | 2013 | 79 | 0.090 |
Why?
| | Serotonin Receptor Agonists | 4 | 2013 | 27 | 0.090 |
Why?
| | Adrenocorticotropic Hormone | 6 | 2004 | 147 | 0.090 |
Why?
| | Blood-Brain Barrier | 2 | 2009 | 160 | 0.090 |
Why?
| | Oncogene Proteins v-fos | 4 | 2015 | 11 | 0.090 |
Why?
| | Receptors, Cholecystokinin | 1 | 1992 | 9 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 2010 | 154 | 0.090 |
Why?
| | Lipopeptides | 1 | 2012 | 17 | 0.090 |
Why?
| | Cytoskeletal Proteins | 2 | 2010 | 156 | 0.090 |
Why?
| | Somatostatin | 1 | 1992 | 53 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 1992 | 56 | 0.090 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 563 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2010 | 273 | 0.090 |
Why?
| | Association Learning | 4 | 2007 | 70 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 138 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2013 | 88 | 0.090 |
Why?
| | Tetracyclines | 1 | 2012 | 16 | 0.090 |
Why?
| | Antigens | 3 | 2003 | 348 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 171 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2016 | 335 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2012 | 88 | 0.090 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 172 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2010 | 187 | 0.090 |
Why?
| | DNA Primers | 2 | 2010 | 505 | 0.090 |
Why?
| | Phenylurea Compounds | 1 | 1992 | 119 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 425 | 0.080 |
Why?
| | Mice, Inbred CBA | 1 | 2011 | 57 | 0.080 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 89 | 0.080 |
Why?
| | Vasodilation | 1 | 2014 | 521 | 0.080 |
Why?
| | Sensation | 1 | 1991 | 55 | 0.080 |
Why?
| | Superoxides | 2 | 2022 | 198 | 0.080 |
Why?
| | Peptide Fragments | 3 | 2011 | 693 | 0.080 |
Why?
| | Rats, Inbred BN | 4 | 2012 | 56 | 0.080 |
Why?
| | Stroke | 2 | 2018 | 1270 | 0.080 |
Why?
| | Endocrine Glands | 1 | 1990 | 14 | 0.080 |
Why?
| | Heart Arrest | 1 | 2015 | 410 | 0.080 |
Why?
| | Phenylephrine | 1 | 1990 | 74 | 0.080 |
Why?
| | GABA Agonists | 4 | 2008 | 24 | 0.080 |
Why?
| | Benzylidene Compounds | 1 | 2010 | 20 | 0.080 |
Why?
| | Muscles | 1 | 1991 | 330 | 0.080 |
Why?
| | Prostaglandins | 2 | 2007 | 94 | 0.080 |
Why?
| | Drug Combinations | 2 | 2009 | 396 | 0.080 |
Why?
| | Food Preferences | 2 | 2008 | 126 | 0.080 |
Why?
| | Sphingolipids | 1 | 2010 | 83 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 669 | 0.080 |
Why?
| | Protein Interaction Mapping | 1 | 2010 | 105 | 0.080 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2009 | 14 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 232 | 0.080 |
Why?
| | Mitochondria | 1 | 2016 | 992 | 0.080 |
Why?
| | Receptors, Interleukin-1 Type I | 2 | 2011 | 25 | 0.080 |
Why?
| | Histamine | 1 | 2009 | 52 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 260 | 0.080 |
Why?
| | Stress Disorders, Traumatic | 1 | 2009 | 25 | 0.080 |
Why?
| | Bradykinin | 1 | 2009 | 49 | 0.080 |
Why?
| | Dimethyl Sulfoxide | 1 | 2009 | 42 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 222 | 0.080 |
Why?
| | Afferent Pathways | 3 | 2005 | 46 | 0.080 |
Why?
| | Infusion Pumps | 1 | 2009 | 33 | 0.080 |
Why?
| | Motor Neurons | 1 | 2012 | 236 | 0.070 |
Why?
| | Eating | 3 | 2000 | 387 | 0.070 |
Why?
| | Injections, Intravenous | 3 | 1998 | 197 | 0.070 |
Why?
| | Amnesia, Retrograde | 2 | 2006 | 6 | 0.070 |
Why?
| | Immunoglobulin M | 4 | 2001 | 265 | 0.070 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 66 | 0.070 |
Why?
| | Toll-Like Receptor 9 | 1 | 2009 | 37 | 0.070 |
Why?
| | Perception | 1 | 1992 | 378 | 0.070 |
Why?
| | Lactams, Macrocyclic | 1 | 2009 | 51 | 0.070 |
Why?
| | Benzoquinones | 1 | 2009 | 46 | 0.070 |
Why?
| | Central Nervous System Infections | 1 | 2009 | 35 | 0.070 |
Why?
| | CpG Islands | 1 | 2009 | 163 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 344 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 369 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2906 | 0.070 |
Why?
| | Spatial Behavior | 1 | 2008 | 24 | 0.070 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 176 | 0.070 |
Why?
| | Age Factors | 7 | 2010 | 3342 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2012 | 541 | 0.070 |
Why?
| | RAW 264.7 Cells | 2 | 2019 | 48 | 0.070 |
Why?
| | Sex Factors | 2 | 2012 | 2105 | 0.070 |
Why?
| | Ligands | 1 | 2010 | 665 | 0.070 |
Why?
| | beta-Adrenergic Receptor Kinases | 1 | 2007 | 4 | 0.060 |
Why?
| | RNA, Antisense | 1 | 2007 | 18 | 0.060 |
Why?
| | Drugs, Investigational | 1 | 2007 | 31 | 0.060 |
Why?
| | Safety | 3 | 2008 | 358 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2188 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 385 | 0.060 |
Why?
| | Cholesterol | 2 | 2003 | 408 | 0.060 |
Why?
| | Foreign-Body Reaction | 1 | 2007 | 34 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1163 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.060 |
Why?
| | GABA-A Receptor Agonists | 3 | 2011 | 17 | 0.060 |
Why?
| | Receptors, Serotonin | 2 | 1997 | 34 | 0.060 |
Why?
| | Stereoisomerism | 2 | 2019 | 103 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 4075 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2005 | 762 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 76 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2006 | 146 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1356 | 0.060 |
Why?
| | Antibodies, Blocking | 1 | 2005 | 37 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 1038 | 0.060 |
Why?
| | Centrifugation | 1 | 2005 | 28 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2006 | 102 | 0.060 |
Why?
| | Peptides | 2 | 2009 | 998 | 0.060 |
Why?
| | Electric Stimulation | 4 | 2011 | 276 | 0.060 |
Why?
| | Blotting, Western | 3 | 2013 | 1179 | 0.060 |
Why?
| | Cell Survival | 3 | 2019 | 1100 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Reinforcement Schedule | 3 | 2017 | 25 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1399 | 0.060 |
Why?
| | Complement C5a | 1 | 2005 | 54 | 0.050 |
Why?
| | Hormone Antagonists | 3 | 2016 | 33 | 0.050 |
Why?
| | Complement C3a | 1 | 2005 | 40 | 0.050 |
Why?
| | Adrenal Glands | 2 | 2018 | 76 | 0.050 |
Why?
| | Computer Simulation | 1 | 2009 | 1003 | 0.050 |
Why?
| | Carbenoxolone | 1 | 2004 | 1 | 0.050 |
Why?
| | Glycyrrhizic Acid | 1 | 2004 | 3 | 0.050 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 12 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1048 | 0.050 |
Why?
| | Electric Countershock | 2 | 1984 | 126 | 0.050 |
Why?
| | Nerve Compression Syndromes | 1 | 2004 | 22 | 0.050 |
Why?
| | Stress, Mechanical | 1 | 2007 | 494 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2012 | 2970 | 0.050 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2004 | 30 | 0.050 |
Why?
| | Cell Separation | 1 | 2005 | 305 | 0.050 |
Why?
| | Epilepsy | 1 | 2009 | 390 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2004 | 45 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1061 | 0.050 |
Why?
| | Adenoviridae | 1 | 2005 | 199 | 0.050 |
Why?
| | Catalase | 1 | 2004 | 134 | 0.050 |
Why?
| | N-Methylaspartate | 1 | 2004 | 43 | 0.050 |
Why?
| | Binding Sites | 2 | 2018 | 1310 | 0.050 |
Why?
| | Hypothermia | 1 | 2004 | 53 | 0.050 |
Why?
| | Peripheral Nervous System | 1 | 2003 | 20 | 0.050 |
Why?
| | Sample Size | 1 | 2004 | 121 | 0.050 |
Why?
| | Receptors, Opioid, kappa | 2 | 1994 | 9 | 0.050 |
Why?
| | Hydrocortisone | 5 | 2009 | 298 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 1 | 2023 | 38 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2010 | 364 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2024 | 98 | 0.050 |
Why?
| | Mental Recall | 2 | 1995 | 222 | 0.050 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 14 | 0.050 |
Why?
| | Lymph Nodes | 3 | 2001 | 503 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2009 | 592 | 0.050 |
Why?
| | Pressure | 1 | 2004 | 226 | 0.050 |
Why?
| | Immunoglobulin G | 4 | 2002 | 892 | 0.050 |
Why?
| | Neck | 2 | 2001 | 108 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 372 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2002 | 18 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| | Adult | 4 | 2022 | 40777 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2003 | 72 | 0.050 |
Why?
| | Immobility Response, Tonic | 2 | 2013 | 6 | 0.050 |
Why?
| | Reflex | 2 | 1994 | 70 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 372 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 308 | 0.050 |
Why?
| | Social Isolation | 1 | 2003 | 74 | 0.050 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 11 | 0.040 |
Why?
| | Psychomotor Performance | 3 | 2015 | 324 | 0.040 |
Why?
| | Antioxidants | 2 | 2022 | 550 | 0.040 |
Why?
| | Glycoproteins | 1 | 2024 | 354 | 0.040 |
Why?
| | NADPH Oxidase 2 | 1 | 2022 | 32 | 0.040 |
Why?
| | Death, Sudden | 1 | 1982 | 26 | 0.040 |
Why?
| | Lumbar Vertebrae | 1 | 2004 | 252 | 0.040 |
Why?
| | Nodose Ganglion | 2 | 1998 | 5 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 337 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 1995 | 418 | 0.040 |
Why?
| | Myelin Sheath | 1 | 2023 | 166 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 2 | 2011 | 181 | 0.040 |
Why?
| | Ventricular Fibrillation | 1 | 1982 | 64 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2022 | 162 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 288 | 0.040 |
Why?
| | Stem Cells | 1 | 2006 | 628 | 0.040 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 171 | 0.040 |
Why?
| | Interferon-gamma | 4 | 2001 | 784 | 0.040 |
Why?
| | Viral Proteins | 1 | 2024 | 350 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3542 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 499 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3413 | 0.040 |
Why?
| | Acute Disease | 2 | 2001 | 1036 | 0.040 |
Why?
| | Protein Conformation | 2 | 2018 | 938 | 0.040 |
Why?
| | Epinephrine | 3 | 2002 | 158 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 101 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 331 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2020 | 6 | 0.040 |
Why?
| | Injections | 2 | 2013 | 199 | 0.040 |
Why?
| | Organ Size | 1 | 2001 | 461 | 0.040 |
Why?
| | Aminopyridines | 2 | 2013 | 129 | 0.040 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2011 | 39 | 0.040 |
Why?
| | Rodentia | 1 | 2020 | 61 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2129 | 0.040 |
Why?
| | Crisis Intervention | 1 | 2020 | 37 | 0.040 |
Why?
| | Depression | 2 | 2008 | 1546 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2003 | 243 | 0.040 |
Why?
| | Receptors, Mineralocorticoid | 1 | 1999 | 11 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 43 | 0.040 |
Why?
| | Alzheimer Disease | 2 | 2020 | 630 | 0.040 |
Why?
| | Subarachnoid Space | 1 | 1999 | 8 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 68 | 0.040 |
Why?
| | Urocortins | 3 | 2004 | 24 | 0.040 |
Why?
| | Paresis | 1 | 1999 | 30 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 1999 | 25 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Coronary Disease | 1 | 1982 | 381 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1997 | 0.040 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 51 | 0.040 |
Why?
| | Fluorescent Dyes | 2 | 2012 | 333 | 0.040 |
Why?
| | Pyrimidines | 2 | 2003 | 530 | 0.040 |
Why?
| | Immunity | 1 | 2000 | 140 | 0.040 |
Why?
| | alpha-MSH | 1 | 1998 | 6 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.040 |
Why?
| | Acute-Phase Reaction | 1 | 1998 | 37 | 0.040 |
Why?
| | Cerebellum | 1 | 2000 | 224 | 0.040 |
Why?
| | Glossopharyngeal Nerve | 1 | 1998 | 11 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1923 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2001 | 68 | 0.030 |
Why?
| | Optical Fibers | 1 | 2018 | 17 | 0.030 |
Why?
| | Limbic Lobe | 1 | 2018 | 3 | 0.030 |
Why?
| | Neuroanatomical Tract-Tracing Techniques | 1 | 2018 | 5 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 371 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 365 | 0.030 |
Why?
| | Stilbamidines | 1 | 2018 | 9 | 0.030 |
Why?
| | Injections, Epidural | 1 | 1998 | 28 | 0.030 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 70 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2005 | 652 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2020 | 268 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2009 | 77 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 2018 | 94 | 0.030 |
Why?
| | Cell Proliferation | 3 | 2012 | 2507 | 0.030 |
Why?
| | Isonicotinic Acids | 1 | 1997 | 2 | 0.030 |
Why?
| | Receptors, GABA | 1 | 1997 | 13 | 0.030 |
Why?
| | Thermosensing | 2 | 1997 | 12 | 0.030 |
Why?
| | Sucrose | 2 | 2008 | 114 | 0.030 |
Why?
| | Oxytocics | 1 | 1997 | 15 | 0.030 |
Why?
| | Biguanides | 1 | 1997 | 10 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 109 | 0.030 |
Why?
| | Amnesia, Anterograde | 2 | 2008 | 7 | 0.030 |
Why?
| | Pyrroles | 1 | 1999 | 220 | 0.030 |
Why?
| | Mannose | 1 | 2017 | 23 | 0.030 |
Why?
| | Baclofen | 1 | 1997 | 21 | 0.030 |
Why?
| | Analgesia, Epidural | 1 | 1997 | 39 | 0.030 |
Why?
| | Histocytochemistry | 1 | 1997 | 78 | 0.030 |
Why?
| | Skin Temperature | 2 | 1994 | 36 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 2 | 2007 | 25 | 0.030 |
Why?
| | Basolateral Nuclear Complex | 1 | 2016 | 11 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 637 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1999 | 372 | 0.030 |
Why?
| | Extracellular Space | 2 | 2009 | 117 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2016 | 115 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 196 | 0.030 |
Why?
| | Nerve Net | 1 | 2000 | 284 | 0.030 |
Why?
| | Period Circadian Proteins | 1 | 2016 | 33 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 58 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1996 | 162 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 130 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1996 | 95 | 0.030 |
Why?
| | Dentate Gyrus | 2 | 2006 | 41 | 0.030 |
Why?
| | Anesthetics, Dissociative | 1 | 2016 | 46 | 0.030 |
Why?
| | Dysgammaglobulinemia | 1 | 1995 | 2 | 0.030 |
Why?
| | IgG Deficiency | 1 | 1995 | 6 | 0.030 |
Why?
| | Leukocytes | 2 | 2011 | 296 | 0.030 |
Why?
| | Optogenetics | 1 | 2016 | 103 | 0.030 |
Why?
| | Saccharin | 1 | 1995 | 9 | 0.030 |
Why?
| | Animal Diseases | 1 | 2015 | 9 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 1995 | 87 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1995 | 49 | 0.030 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Capsaicin | 1 | 2015 | 30 | 0.030 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1994 | 6 | 0.030 |
Why?
| | Chlorisondamine | 1 | 1994 | 3 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1999 | 391 | 0.030 |
Why?
| | Adrenal Medulla | 1 | 1994 | 10 | 0.030 |
Why?
| | Blood Proteins | 1 | 1997 | 239 | 0.030 |
Why?
| | CD4 Antigens | 1 | 1995 | 137 | 0.030 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2014 | 11 | 0.030 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 288 | 0.030 |
Why?
| | Substance P | 1 | 1994 | 38 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2005 | 318 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 561 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 1994 | 67 | 0.030 |
Why?
| | Ganglionectomy | 1 | 1994 | 2 | 0.030 |
Why?
| | Decerebrate State | 1 | 1994 | 3 | 0.030 |
Why?
| | Kupffer Cells | 1 | 1994 | 52 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 539 | 0.030 |
Why?
| | Ganglia, Sympathetic | 1 | 1994 | 14 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 331 | 0.030 |
Why?
| | Auditory Cortex | 1 | 1994 | 46 | 0.030 |
Why?
| | Valine | 1 | 2014 | 83 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 305 | 0.030 |
Why?
| | Basal Ganglia | 1 | 1994 | 57 | 0.030 |
Why?
| | Adiposity | 1 | 2018 | 532 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2016 | 242 | 0.020 |
Why?
| | Respiration | 1 | 2014 | 206 | 0.020 |
Why?
| | Biological Transport | 1 | 1995 | 424 | 0.020 |
Why?
| | Treatment Outcome | 3 | 2016 | 11772 | 0.020 |
Why?
| | Weight Loss | 2 | 2009 | 858 | 0.020 |
Why?
| | Pregnancy | 3 | 2017 | 7202 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2013 | 26 | 0.020 |
Why?
| | Receptors, Opioid, delta | 1 | 1992 | 10 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 1992 | 18 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2012 | 43 | 0.020 |
Why?
| | Anesthetics | 1 | 1993 | 99 | 0.020 |
Why?
| | Spodoptera | 1 | 2012 | 40 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 130 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 23 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2012 | 50 | 0.020 |
Why?
| | Receptors, IgG | 1 | 2012 | 77 | 0.020 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 228 | 0.020 |
Why?
| | Gliosarcoma | 1 | 1992 | 8 | 0.020 |
Why?
| | Biological Assay | 1 | 2012 | 130 | 0.020 |
Why?
| | Lymphocyte Transfusion | 1 | 1992 | 20 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 94 | 0.020 |
Why?
| | Biophysics | 1 | 2012 | 75 | 0.020 |
Why?
| | Kinetics | 2 | 2006 | 1567 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 40 | 0.020 |
Why?
| | Dimerization | 1 | 2012 | 189 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1067 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 75 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 126 | 0.020 |
Why?
| | Azoles | 1 | 2011 | 4 | 0.020 |
Why?
| | Nitrobenzenes | 1 | 2011 | 15 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2011 | 40 | 0.020 |
Why?
| | Physical Exertion | 1 | 1992 | 205 | 0.020 |
Why?
| | Foot | 1 | 1992 | 103 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2011 | 45 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 283 | 0.020 |
Why?
| | Molecular Mimicry | 1 | 2011 | 36 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 204 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 2046 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 338 | 0.020 |
Why?
| | Rotarod Performance Test | 1 | 2011 | 15 | 0.020 |
Why?
| | Biotin | 1 | 2011 | 32 | 0.020 |
Why?
| | Reflex, Righting | 1 | 2011 | 15 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2011 | 30 | 0.020 |
Why?
| | Dextrans | 1 | 2011 | 84 | 0.020 |
Why?
| | Electrophysiology | 1 | 2011 | 218 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 165 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1990 | 44 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1992 | 440 | 0.020 |
Why?
| | Sphingosine | 1 | 2010 | 47 | 0.020 |
Why?
| | Vasopressins | 1 | 1990 | 61 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 855 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 475 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2010 | 44 | 0.020 |
Why?
| | Lysophospholipids | 1 | 2010 | 80 | 0.020 |
Why?
| | PC12 Cells | 1 | 2009 | 42 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 143 | 0.020 |
Why?
| | Dominance-Subordination | 1 | 2009 | 16 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2009 | 32 | 0.020 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.020 |
Why?
| | Genes, fos | 1 | 2009 | 36 | 0.020 |
Why?
| | Vaccination | 1 | 2018 | 1426 | 0.020 |
Why?
| | Esters | 1 | 2009 | 71 | 0.020 |
Why?
| | Temperature | 1 | 1992 | 633 | 0.020 |
Why?
| | Drinking | 2 | 1999 | 44 | 0.020 |
Why?
| | Adaptation, Physiological | 2 | 2003 | 560 | 0.020 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2008 | 7 | 0.020 |
Why?
| | Aldehydes | 1 | 2009 | 139 | 0.020 |
Why?
| | Electromyography | 1 | 1991 | 419 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 319 | 0.020 |
Why?
| | Myelin Proteins | 1 | 2008 | 45 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 381 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 257 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 295 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 630 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1995 | 1140 | 0.020 |
Why?
| | Parietal Lobe | 1 | 2008 | 61 | 0.020 |
Why?
| | Action Potentials | 1 | 2011 | 502 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 777 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 1995 | 956 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 342 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2009 | 138 | 0.020 |
Why?
| | Naproxen | 1 | 2007 | 21 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 187 | 0.020 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 9 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2009 | 368 | 0.020 |
Why?
| | Endotoxemia | 1 | 2007 | 86 | 0.020 |
Why?
| | Mesentery | 2 | 1998 | 44 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2883 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2009 | 246 | 0.020 |
Why?
| | Gyrus Cinguli | 1 | 2006 | 97 | 0.020 |
Why?
| | Heart Rate | 1 | 1990 | 855 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 730 | 0.020 |
Why?
| | Thiocarbamates | 1 | 2005 | 6 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 194 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2012 | 967 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 49 | 0.010 |
Why?
| | Phenotype | 2 | 2009 | 3155 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 72 | 0.010 |
Why?
| | Locus Coeruleus | 1 | 2005 | 25 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2005 | 22 | 0.010 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 2004 | 2 | 0.010 |
Why?
| | Proline | 1 | 2005 | 82 | 0.010 |
Why?
| | Pro-Opiomelanocortin | 1 | 2004 | 20 | 0.010 |
Why?
| | Aminoglutethimide | 1 | 2004 | 4 | 0.010 |
Why?
| | Metyrapone | 1 | 2004 | 5 | 0.010 |
Why?
| | Serotonin Agents | 1 | 2004 | 8 | 0.010 |
Why?
| | Motor Cortex | 1 | 2005 | 65 | 0.010 |
Why?
| | Rats, Mutant Strains | 1 | 2004 | 19 | 0.010 |
Why?
| | Reptilian Proteins | 1 | 2004 | 3 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 779 | 0.010 |
Why?
| | Group II Phospholipases A2 | 1 | 2004 | 10 | 0.010 |
Why?
| | Receptors, Leptin | 1 | 2004 | 25 | 0.010 |
Why?
| | Electrochemistry | 1 | 2004 | 70 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2004 | 82 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1734 | 0.010 |
Why?
| | Catecholamines | 1 | 2004 | 88 | 0.010 |
Why?
| | Concanavalin A | 1 | 2003 | 72 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2440 | 0.010 |
Why?
| | Serotonin 5-HT1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 2003 | 5 | 0.010 |
Why?
| | Electrolysis | 1 | 2003 | 2 | 0.010 |
Why?
| | Immobilization | 1 | 2003 | 54 | 0.010 |
Why?
| | Nanoparticles | 1 | 2010 | 517 | 0.010 |
Why?
| | HIV Infections | 1 | 1999 | 3193 | 0.010 |
Why?
| | Blood Pressure | 1 | 1990 | 1779 | 0.010 |
Why?
| | Sleep | 1 | 2011 | 888 | 0.010 |
Why?
| | Sepsis | 1 | 2010 | 664 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2158 | 0.010 |
Why?
| | Oxathiins | 1 | 2002 | 1 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2003 | 201 | 0.010 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2004 | 194 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1984 | 137 | 0.010 |
Why?
| | Drug Resistance | 1 | 2003 | 145 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 243 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 1992 | 1329 | 0.010 |
Why?
| | Aniline Compounds | 1 | 2003 | 120 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 756 | 0.010 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2001 | 6 | 0.010 |
Why?
| | Wallerian Degeneration | 1 | 2001 | 4 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1134 | 0.010 |
Why?
| | Tachycardia | 1 | 1982 | 57 | 0.010 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2002 | 59 | 0.010 |
Why?
| | Epitopes | 1 | 2003 | 473 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2003 | 360 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 8 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2001 | 164 | 0.010 |
Why?
| | Emotions | 1 | 2006 | 574 | 0.010 |
Why?
| | Immunoglobulin Isotypes | 1 | 2001 | 36 | 0.010 |
Why?
| | Luminescent Measurements | 1 | 2001 | 75 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 309 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2006 | 910 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2004 | 337 | 0.010 |
Why?
| | Spironolactone | 1 | 2001 | 40 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 128 | 0.010 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 199 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2005 | 440 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 312 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1767 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 37 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1998 | 30 | 0.010 |
Why?
| | Prognosis | 1 | 2007 | 4316 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1998 | 128 | 0.010 |
Why?
| | Administration, Oral | 1 | 2001 | 866 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1998 | 24 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5423 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1162 | 0.010 |
Why?
| | Butoxamine | 1 | 1996 | 1 | 0.010 |
Why?
| | Atenolol | 1 | 1996 | 8 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 1996 | 24 | 0.010 |
Why?
| | Propranolol | 1 | 1996 | 44 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 36 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1996 | 154 | 0.010 |
Why?
| | Diazepam | 1 | 1995 | 33 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 484 | 0.010 |
Why?
| | Anti-Anxiety Agents | 1 | 1995 | 48 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 252 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1995 | 114 | 0.010 |
Why?
| | Cytological Techniques | 1 | 1995 | 27 | 0.010 |
Why?
| | Nylons | 1 | 1995 | 24 | 0.010 |
Why?
| | Jugular Veins | 1 | 1994 | 42 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 8057 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1994 | 26 | 0.010 |
Why?
| | Methoxyflurane | 1 | 1993 | 2 | 0.010 |
Why?
| | Chloral Hydrate | 1 | 1993 | 3 | 0.010 |
Why?
| | Halothane | 1 | 1993 | 8 | 0.010 |
Why?
| | Pentobarbital | 1 | 1993 | 17 | 0.010 |
Why?
| | Xylazine | 1 | 1993 | 15 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1992 | 23 | 0.010 |
Why?
| | Cholesterol, Dietary | 1 | 1992 | 15 | 0.010 |
Why?
| | Cold Temperature | 1 | 1993 | 206 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 246 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1995 | 1132 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 177 | 0.010 |
Why?
| | Obesity | 1 | 2004 | 3116 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 886 | 0.000 |
Why?
| | Dietary Fats | 1 | 1992 | 308 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1984 | 16 | 0.000 |
Why?
| | Adolescent | 1 | 1982 | 22529 | 0.000 |
Why?
| | Aged | 1 | 1982 | 26153 | 0.000 |
Why?
| | Recurrence | 1 | 1984 | 1138 | 0.000 |
Why?
| | Electrocardiography | 1 | 1984 | 665 | 0.000 |
Why?
| | Middle Aged | 1 | 1982 | 36215 | 0.000 |
Why?
|
|
Watkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|